John Lukesh

Dr. John Lukesh

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2020 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
RHRynne A. Hankins
Rynne A. Hankins
SSS. Israel Suarez
S. Israel Suarez
MKMadison A. Kalk
Madison A. Kalk
NGNolan M. Green
Nolan M. Green
MHMegan N. Harty
Megan N. Harty
JLJohn Lukesh
John Lukesh

5 March 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
QHQiwei Hu
Qiwei Hu
JLJohn Lukesh
John Lukesh
Hydrogen sulfide (H2S) is an endogenous signaling molecule that greatly influences several important (patho)physiological processes related to cardiovascular health and disease, including vasodilation, angiogenesis, inflammation, and cellular redox homeostasis. Consequently, H2S supplementation is an emerging area of interest, especially for the treatment of cardiovascular-related diseases. To fully unlock the medicinal properties of hydrogen sulfide, however, the development and refinement of H2S releasing compounds (or donors) are required to augment its bioavailability and to better mimic its natural enzymatic production. Categorizing donors by the biological stimulus that triggers their H2S release, this review highlights the fundamental chemistry and releasing mechanisms of a range of H2S donors that have exhibited promising protective effects in models of myocardial ischemia-reperfusion (MI/R) injury and cancer chemotherapy-induced cardiotoxicity, specifically. Thus, in addition to serving as important investigative tools that further advance our knowledge and understanding of H2S chemical biology, the compounds highlighted in this review have the potential to serve as vital therapeutic agents for the treatment (or prevention) of various cardiomyopathies.

12 December 2019 in Organic & Biomolecular Chemistry
Verified
Journal Article
Open access
PDF file
SSS. Israel Suarez
S. Israel Suarez
CWCaroline C. Warner
Caroline C. Warner
HBHeather Brown-Harding
Heather Brown-Harding
ATAndrea M. Thooft
Andrea M. Thooft
BVBrett VanVeller
Brett VanVeller
JLJohn Lukesh
John Lukesh
A robust lipophilic dye, based on the structures of the benzothiadiazole heterocycle, was shown to be a potent fluorescent stain for the selective imaging of lipid droplets (LDs) within both live and fixed human cells. Its small molecular framework, large Stokes shift, and vastly improved photostability over that of the current status quo, Nile Red, highlight its tremendous potential as a versatile chemical tool for facilitating LD imaging and research.

11 November 2023 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
QHQiwei Hu
Qiwei Hu
CZChanglei Zhu
Changlei Zhu
RHRynne A. Hankins
Rynne A. Hankins
AMAllison R. Murmello
Allison R. Murmello
GMGlen S. Marrs
Glen S. Marrs
JLJohn Lukesh
John Lukesh

16 May 2022 in Redox Biology
Verified
Journal Article
Open access
QHQiwei Hu
Qiwei Hu
RYRama D. Yammani
Rama D. Yammani
HBHeather Brown-Harding
Heather Brown-Harding
DSDavid R. Soto-Pantoja
David R. Soto-Pantoja
LPLeslie B. Poole
Leslie B. Poole
JLJohn Lukesh
John Lukesh
Doxorubicin (DOX) is one of the most effective anticancer agents in clinical oncology. Its continued use, however, is severely limited by its dose-dependent cardiotoxicity which stems, in part, from its overproduction of reactive oxygen species (ROS) and often manifests itself as full-blown cardiomyopathy in patients, years after the cessation of treatment. Therefore, identifying DOX analogs, or prodrugs, with a diminished cardiotoxic profile is highly desirable. Herein, we describe a novel, H2O2-responsive DOX hybrid codrug (mutual prodrug) that has been rationally designed to concurrently liberate hydrogen sulfide (H2S), a purported cardioprotectant with anticancer activity, in an effort to maintain the antitumor effects of DOX while simultaneously reducing its cardiotoxic side effects. Experiments with cardiomyoblast cells in culture demonstrated a rapid accumulation of prodrug into the cells, but diminished apoptotic effects compared with DOX, dependent upon its release of H2S. Cells treated with the prodrug exhibited significantly higher Nrf2 activation relative to DOX-treated cells. Preliminary indications, using a mouse triple-negative breast cancer cell line sensitive to DOX treatment, are that the prodrug maintains considerable toxicity against the tumor-inducing cell line, suggesting significant promise for this prodrug as a cardioprotective chemotherapeutic to replace DOX.

7 October 2022 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
QHQiwei Hu
Qiwei Hu
SSS. Israel Suarez
S. Israel Suarez
RHRynne A. Hankins
Rynne A. Hankins
JLJohn Lukesh
John Lukesh